Multiple Myeloma Clinical Trials and Treatments

Plasma cells live in the bone marrow and make the antibodies that fight infection. In multiple myeloma, one plasma cell turns cancerous and copies itself until the marrow fills with identical myeloma cells. Those cells do 3 kinds of damage.

The most common symptoms of Multiple Myeloma include Bone pain, most often in the back or ribs, Bones that break easily, Frequent infections or a fever with no clear cause, Tiredness and shortness of breath from low red blood cells, Easy bruising or bleeding, among others. About 36,000 new US diagnoses expected in 2026 and roughly 203,000 people living with it, which puts myeloma right at the edge of the US rare disease threshold; it is 1.7% of all new cancers (NCI SEER). Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Multiple Myeloma from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. Myeloma is one of the busiest trial fields in all of cancer, with hundreds of recruiting studies, so the question is rarely whether a trial exists but which one fits the number and type of treatments you have already had. The approved drugs fall into classes that trials combine and sequence: proteasome inhibitors (bortezomib, carfilzomib, ixazomib), immunomodulators (thalidomide, lenalidomide, pomalidomide), antibodies such as daratumumab and elotuzumab, high-dose chemotherapy with a stem cell transplant, and newer immune therapies, including CAR T cell therapies and bispecific antibodies, that aim the body's T cells at myeloma cells.

As of September 2026, Trial Friend's curated drug index does not include an FDA-approved treatment specific to Multiple Myeloma. The Treatments section of this page checks FDA drug labels live and lists any approved drug whose label names the condition, and the trials listed below cover the investigational options. The FDA is due to decide on Anito-cel (anitocabtagene autoleucel) by December 23, 2026 and Mezigdomide by May 13, 2027; the FDA calendar page carries the outcome the day it lands.

Multiple Myeloma arises from acquired (somatic) genetic changes in the affected cells, rather than from an inherited variant. Myeloma arises from changes that a single plasma cell acquires during life; the useful tests look at the myeloma cells themselves, not inherited DNA. About 36,000 new US diagnoses expected in 2026 and roughly 203,000 people living with it, which puts myeloma right at the edge of the US rare disease threshold; it is 1.7% of all new cancers (NCI SEER).

For Multiple Myeloma the genetic testing that matters is usually of the tumor or affected blood cells rather than inherited DNA. Myeloma arises from changes that a single plasma cell acquires during life; the useful tests look at the myeloma cells themselves, not inherited DNA.

Those results guide treatment choice and are often the entry requirement for targeted-therapy trials, so ask whether the biopsy was sent for molecular testing and request the report. The Genetic Testing section of this page lists laboratories in the NIH Genetic Testing Registry.

Eligibility for Multiple Myeloma clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Multiple Myeloma clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.